Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL

Late MRD response determines relapse risk overall and in subsets of childhood T-cell ALL: results of the AIEOP-BFM-ALL 2000 study

(2011) M. Schrappe et al.   BLOOD

New markers for minimal residual disease detection in acute lymphoblastic leukemia

(2011) E. Coustan-Smith et al.   BLOOD

Minimal residual disease assessment in childhood acute lymphoblastic leukaemia: a Swedish multi-centre study comparing real-time polymerase chain reaction and multicolour flow cytometry

(2011) Ingrid Thörn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Very early/early relapses of acute lymphoblastic leukemia show unexpected changes of clonal markers and high heterogeneity in response to initial and relapse treatment

(2011) C Eckert et al.   LEUKEMIA

Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study

(2010) V. Conter et al.   BLOOD

Clinical significance of low levels of minimal residual disease at the end of remission induction therapy in childhood acute lymphoblastic leukemia

(2010) P. Stow et al.   BLOOD

Immaturity associated antigens are lost during induction for T cell lymphoblastic leukemia: Implications for minimal residual disease detection

(2010) Mikhail Roshal et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY

Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII/ECOG2993

(2009) Bella Patel et al.   BRITISH JOURNAL OF HAEMATOLOGY

Establishment and validation of a standard protocol for the detection of minimal residual disease in B lineage childhood acute lymphoblastic leukemia by flow cytometry in a multi-center setting;

(2009) J. Irving et al.   HAEMATOLOGICA

Risk of Relapse of Childhood Acute Lymphoblastic Leukemia Is Predicted By Flow Cytometric Measurement of Residual Disease on Day 15 Bone Marrow

(2009) Giuseppe Basso et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality Control of Flow Cytometry Data Analysis for Evaluation of Minimal Residual Disease in Bone Marrow From Acute Leukemia Patients During Treatment

(2009) Elisabet Björklund et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

Standardized MRD quantification in European ALL trials: Proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18–20 September 2008

(2009) M Brüggemann et al.   LEUKEMIA

Treating Childhood Acute Lymphoblastic Leukemia without Cranial Irradiation

(2009) Ching-Hon Pui et al.   NEW ENGLAND JOURNAL OF MEDICINE

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study

(2008) M. J. Borowitz et al.   BLOOD

Standardization of flow cytometric minimal residual disease evaluation in acute lymphoblastic leukemia: Multicentric assessment is feasible

(2008) Michael Norbert Dworzak et al.   CYTOMETRY PART B-CLINICAL CYTOMETRY